

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. The Phase III SWOG-9346 trial showed that intermittent androgen deprivation is inferior to continuous androgen deprivation for patients with hormone-sensitive metastatic prostate cancer.
 - a. True
 - b. False

2. The AFFIRM Phase III trial for men with metastatic castration-resistant prostate cancer (CRPC) previously treated with chemotherapy demonstrated that enzalutamide was superior to placebo with respect to _____.
 - a. Median overall survival
 - b. Radiographic progression-free survival
 - c. Time to PSA progression
 - d. PSA response rate
 - e. All of the above

3. Among patients with CRPC with bone metastases, radium-223 chloride did not have a significant effect on median overall survival or median time to first skeletal-related event in the Phase III ALSYMPCA trial.
 - a. True
 - b. False

4. Interim analysis of the results of the COU-AA-302 Phase III trial of abiraterone acetate versus placebo in chemotherapy-naïve patients with metastatic CRPC demonstrated a statistically significant improvement in _____ with abiraterone acetate.
 - a. Radiographic progression-free survival
 - b. Overall survival
 - c. Both a and b